Tokyo, Japan

Keisuke Mitamura

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Keisuke Mitamura: Innovator in Bispecific Antibody Technology

Introduction

Keisuke Mitamura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. His innovative work has the potential to advance therapeutic and diagnostic methods in medicine.

Latest Patents

Mitamura holds a patent for a bispecific antibody that binds to the transferrin receptor (TfR). This invention encompasses a bispecific antibody in which an N-terminal side polypeptide is linked to an IgG portion that specifically targets TfR. The patent also includes a DNA sequence encoding the bispecific antibody, a vector containing this DNA, and methods for producing the antibody or its fragments. Additionally, it covers therapeutic and diagnostic agents that utilize this bispecific antibody, as well as reagents for detection or measurement.

Career Highlights

Keisuke Mitamura is associated with Kyowa Kirin Co., Ltd., a leading biopharmaceutical company. His work at the company has been instrumental in advancing research and development in antibody technology. With a focus on innovative solutions, he has contributed to the company's mission of improving patient outcomes through cutting-edge therapies.

Collaborations

Mitamura has collaborated with notable colleagues, including Ryosuke Nakano and Masayuki Kai. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of biotechnology.

Conclusion

Keisuke Mitamura's contributions to bispecific antibody technology exemplify the innovative spirit of modern biotechnology. His work not only enhances therapeutic options but also paves the way for future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…